100% agreed Musky, the first two options would take the risk well out of this company.
First two options
- Licensing of ADAPT® technology to existing in-market TAVR and SAVR products
- Supply of ADAPT® treated material for current in-market products
Is the below study the final hurdle to getting these deals signed? Did he say study to be completed over the next couple of months?
Anti-Calcification Comparison Study
Confirm ADAPT® Technology’s superior resistance to calcification vs. a commercially available anti-calcification technology tissue commonly used in surgical and TAVR valves
Obviously, will also help with obtaining FDA fast track designation too.
Great presentation on a totally new company IMO
My thoughts on the AHZ AGM presentation, page-9
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |